Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
Molindone was compared with haloperidol in animal models of tardive dyskinesia. Treatment with molindone for 14 days at 3, 6, 20 and 40 mg/kg, enhanced the stereotyped behavioral response induced by apomorphine and increased the numbered of D-2 dopamine receptors in the striatum (Bmax) labelled by high affinity (Kd = 40 pmol) binding or [3H] spiroperidol in the guinea-pig. Molindone at 1 mg/kg, caused no behavioral supersensitivity or change in the binding of dopamine receptors. Chronic administration of haloperidol (0.1, 0.5 and 5.0 mg/kg) also increased both the behavioral response to apomorphine and the number of dopamine receptors. Haloperidol, at 0.02 and 0.004 mg/kg, had no effect. Molindone potentiated dopaminergic activity in animal models in a similar way to other neuroleptics, suggesting that its use may also result in tardive dyskinesia.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D003342:Corpus Striatum / Q000378:metabolism; D004195:Disease Models, Animal; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D006168:Guinea Pigs; D006220:Haloperidol / Q000633:toxicity*; D006801:Humans; D007211:Indoles / Q000633:toxicity*; D008297:Male; D008972:Molindone / Q000633:toxicity*; D011954:Receptors, Dopamine / Q000378:metabolism; D017448:Receptors, Dopamine D2; D013134:Spiperone / Q000378:metabolism; D013239:Stereotyped Behavior / Q000187:drug effects
D007211:Indoles; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D013134:Spiperone; D006220:Haloperidol; D001058:Apomorphine; D008972:Molindone